a-Gal and other recent findings that have informed our understanding of anaphylaxis

Annals of Allergy, Asthma & Immunology

February  2020 Volume 124, Issue 2, Pages 135-142 CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

•  Recognize that anaphylaxis represents an over-exuberant manifestation of a form of immunity 
    which evolved to combat toxins and other threats to the skin and mucosa.
•  Describer the effects of early oral introduction of allergenic foods and emerging work on the 
    microbiome on management of food allergy.

​​​​​​​*  Compare the features if the a-Gal syndrome ​​​​​​​to other forms of anaphylaxis

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all CME planners, presenters, moderators, authors, reviewers, and other individuals in a position to control and/or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI.

Disclosure of Relevant Financial Relationships
All identified conflicts of interest have been resolved. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Planning Committee

  • Jonathan A. Bernstein, MD (Annals CME Subcommittee): Consultant, Fees: Imedics; Consultant/Principal Investigator, Grants/Fees: Boehringer Ingelheim, GlaxoSmithKline; Consultant/Principal Investigator/Speaker, Grants/Fees: AstraZeneca, CSL Behring, Novartis/Genentech, Shire; Speaker, Fees: Baxalta
  • Guha Krishnaswamy, MD (Annals CME Subcommittee): Clinical Research, Grant: CSL Behring
  • Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief): Clinical Research, Grants: Sanofi, Stallergenes
  • Anna Nowak-Wegrzyn, MD (CME Series Editor, Deputy Editor): Clinical Research, Grant: Nutricia, Nestle, ITN NIH, DBV, Astellas; Speaker, Fees: Nutricia, Nestle, Thermofisher; Contributor, Royalties: UpToDate: Clinical Trial DMC Member: Merck; Board Member: Gerber, IFPIES
  • John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor): Consultant, Other financial gains: DBV Technologies, GlaxoSmithKline, Kaleo; Clinical Research, Grants: AstraZeneca, Boehringer Ingelheim, Novartis

Authors:

  • Thomas A. E. Platts, MD, PhD, Honorarium/Research: Phadia, Thermo Fischer
  • Jeffrey M. Wilson, MD, PhD, Co-Investigator: Fees: NIH


Recognition of Commercial Support: This activity has not received external commercial support.
Copyright Statement: ©2015-2020 ACAAI. All rights reserved. CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at education@acaai.org or 847-427-1200.

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
02/01/2020
Course expires: 
01/31/2022
Rating: 
0

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.